In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $0.25 in the prior trading day, BioAffinity Technologies Inc (NASDAQ: BIAF) closed at $12.55M, up 612079%. In other words, the price has increased by $612079 from its previous closing price. On the day, 0.61 million shares were traded. BIAF stock price reached its highest trading level at $0.2534 during the session, while it also had its lowest trading level at $0.2344.
Ratios:
Our goal is to gain a better understanding of BIAF by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.53 and its Current Ratio is at 0.55. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.48.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIAF now has a Market Capitalization of 6727825 and an Enterprise Value of 7226465. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.76 while its Price-to-Book (P/B) ratio in mrq is 3.00. Its current Enterprise Value per Revenue stands at 0.82 whereas that against EBITDA is -0.801.
Stock Price History:
The Beta on a monthly basis for BIAF is 2.57, which has changed by -0.87578946 over the last 52 weeks, in comparison to a change of 0.09544468 over the same period for the S&P500. Over the past 52 weeks, BIAF has reached a high of $2.99, while it has fallen to a 52-week low of $0.16. The 50-Day Moving Average of the stock is -31.76%, while the 200-Day Moving Average is calculated to be -73.67%.
Shares Statistics:
The stock has traded on average 12.55M shares per day over the past 3-months and 1603930 shares per day over the last 10 days, according to various share statistics. A total of 28.46M shares are outstanding, with a floating share count of 20.25M. Insiders hold about 28.84% of the company’s shares, while institutions hold 1.80% stake in the company. Shares short for BIAF as of 1748563200 were 1608141 with a Short Ratio of 0.13, compared to 1745971200 on 289273. Therefore, it implies a Short% of Shares Outstanding of 1608141 and a Short% of Float of 6.43.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Its stock is currently analyzed by 1.0 different market analysts. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.09 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.4 and -$0.4 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is -$0.18, with 1.0 analysts recommending between -$0.18 and -$0.18.
Revenue Estimates
1 analysts predict $1.51M in revenue for the current quarter. It ranges from a high estimate of $1.51M to a low estimate of $1.51M. As of the current estimate, BioAffinity Technologies Inc’s year-ago sales were $2.4MFor the next quarter, 1 analysts are estimating revenue of $1.55M. There is a high estimate of $1.55M for the next quarter, whereas the lowest estimate is $1.55M.
A total of 1 analysts have provided revenue estimates for BIAF’s current fiscal year. The highest revenue estimate was $6.5M, while the lowest revenue estimate was $6.5M, resulting in an average revenue estimate of $6.5M. In the same quarter a year ago, actual revenue was $9.36MBased on 1 analysts’ estimates, the company’s revenue will be $7.8M in the next fiscal year. The high estimate is $7.8M and the low estimate is $7.8M.
